In the US alone, one in five adults experiences a form of mental illness each year. New medicines are urgently needed, as current therapies fail to work in up to a third of patients.
AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the ne
Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.
One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to
AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival
Johnson & Johnson’s ‘Swiss army knife’ for autoimmune diseases – FcRn inhibitor nipocalimab – has shown efficacy in Sjogren’s disease (SjD), an autoimmune condition that affects million